Marlies P. Schijven

Oct 4, 2024 | nature.com | M. Louis Handoko |Susan Stienen |Marlies P. Schijven |Folkert W. Asselbergs |Aeilko H. Zwinderman

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03238-6, published online 31 August 2024. In the version of the article initially published, the traces in Fig. 3 appeared with an incorrect 180° rotation, with y-axis units ranging from 0.5–1.0, rather than 0.0–0.5. The caption to Fig. 3, which originally read “The red Kaplan–Meier curve represents the time until OMT in the treatment group, and the blue curve represents the time until OMT in the usual care group.

Aug 31, 2024 | nature.com | M. Louis Handoko |Susan Stienen |Marlies P. Schijven |Folkert W. Asselbergs |Aeilko H. Zwinderman

AbstractGuideline-directed medical therapy (GDMT) has clear benefits on morbidity and mortality in patients with heart failure; however, GDMT use remains low. In the multicenter, open-label, investigator-initiated ADMINISTER trial, patients (n = 150) diagnosed with heart failure and reduced ejection fraction (HFrEF) were randomized (1:1) to receive usual care or a strategy using digital consults (DCs).